Neonatal leukaemia is defined as occurring within the first 28 days of life and most, if not all, cases are congenital. With the exception of Down syndrome-associated transient abnormal myelopoiesis, which is not considered here, neonatal leukaemias are rare. In two-thirds of patients the disease manifests as an acute myeloid leukaemia, frequently with monocytic/monoblastic characteristics. Most other cases are acute lymphoblastic leukaemia, particularly B lineage, but some are mixed phenotype or blastic plasmacytoid dendritic cell neoplasms. The most frequently observed cytogenetic/ molecular abnormality is t(4;11)(q21.3;q23.3)/KMT2A-AFF1 followed by t(1;22)(p13.3;q13.1)/RBM15-MKL1 and t(8;16) (p11.2;p13.3)/KAT6A-CREBBP. Common clinical features include prominent hepatosplenomegaly and a high incidence of skin involvement, sometimes in the absence of bone marrow disease. A distinctive feature is the occurrence of spontaneous remission in some cases, particularly in association with t(8;16). In this review, we summarise current knowledge of the clinical, cytogenetic and molecular features of neonatal leukaemia and discuss clinical management of these cases.
Background
It is now well established that the first mutation underlying childhood leukaemia often occurs in utero. In such cases there is rarely a history of neonatal clinical or haematological abnormality and the mutations are assumed to be 'silent' at birth and for some time thereafter, requiring a 'second hit' for leukaemia to develop. In contrast, in neonatal (or congenital) leukaemia, all the necessary mutations have occurred in utero and the baby is born with the clinical and haematological features of leukaemia already evident. This review focuses on neonatal leukaemia, i.e. leukaemia presenting in the first 28 days of life. We have not included Down syndrome-associated neonatal leukaemia, usually presenting as transient abnormal myelopoiesis (TAM), even though this is the most common neonatal leukaemia, as this has been reviewed recently (Roberts & Izraeli, 2014) .
Epidemiology
Non-Down syndrome (non-DS) neonatal leukaemias are known to be rare. Accurate estimates are lacking, however, as most reports of leukaemia incidence in neonates also includes infants and/or older children. Retrospective studies in the Netherlands and Brazil suggest that neonatal leukaemia accounts for <1% of all childhood leukaemia (Bresters et al, 2002; Moura et al, 2015) . In the Netherlands study (Bresters et al, 2002) , the authors identified 15 cases during the 25-year study period from 1975 to 1999 (i.e. less than 1 case per year) compared to 122 children with leukaemia aged 0-14 years in a single year (1999) . The study from Brazil identified 35 cases of non-DS leukaemia in neonates, also over a 25-year period (1990-2013) compared to 404 cases of leukaemia in all children under the age of 12 months over the same time period (Moura et al, 2015) . A widely quoted study from almost 40 years ago reported an annual incidence of leukaemia in children diagnosed in the first year of life as 31Á8 per million live births (Bader & Miller, 1979) . Taken together, these data suggest an incidence of neonatal leukaemia of~3 cases/million live births or~2 cases per year in the UK.
From the reported cases and case series, there is no significant difference in gender (Bresters et al, 2002; Moura et al, 2015) despite a slight excess of females with infant leukaemia (Biondi et al, 2000) . There is also no apparent bias in the ethnicity of affected neonates, although leukaemia in neonates and infants has been reported to be extremely rare in Africa (Williams et al, 2014) . No family history is available in the vast majority of reported cases, although a unique family has been reported in which two siblings suffered from neonatal acute leukaemia, one having del(4q31) and the other having normal cytogenetic analysis (Agrawal et al, 2011) .
Neonatal leukaemias have a range of immunophenotypes -acute myeloid leukaemia (AML), acute lymphoblastic leukaemia (ALL), mixed phenotype acute leukaemia (MPAL) or, rarely, blastic plasmacytoid dendritic cell neoplasm. AML is more common than ALL, representing about two-thirds of cases (Bresters et al, 2002) . Interestingly, there is increasing evidence from a large number of individual case reports of the occurrence of neonatal leukaemias that undergo spontaneous remission, although robust corroborating evidence is lacking in some of these cases (see below).
Clinical and laboratory features
The most common clinical signs are hepatomegaly, splenomegaly and skin lesions (leukaemia cutis). Jaundice, ascites and pleural effusions are also fairly common while lymphadenopathy is less so. Hepatic failure can lead to death despite regression of the leukaemia (Lazure et al, 2003) . Overall, central nervous system (CNS) infiltration is reported in around 50% of all cases and manifests with a bulging fontanelle, papilloedema and retinal haemorrhages as well as a reduced level of consciousness (which can also be due to leucostasis associated with hyperleucocytosis). Babies with hyperleucocytosis can also have respiratory distress with hypoxia and acidosis, cardiac failure and renal failure (Weis et al, 1985; Heikenheimo et al, 1994; Ferguson et al, 2005; Van Dongen et al, 2009) .
Cutaneous infiltrates are particularly a feature of neonatal AML, being present in about two-thirds of such babies and can occur without any peripheral blood or bone marrow involvement (Zhang et al, 2006; Lee et al, 2013) . Typically, leukaemia cutis manifests as generalised firm nodules, which may be blue, red, brown or purple. The appearance has been described as a 'blueberry muffin rash' (Fig. 1 ) although this is not specific for neonatal leukaemia, being seen occasionally in neuroblastoma as well as in congenital infections and in non-malignant conditions associated with extramedullary haemopoiesis, such as severe haemolytic anaemias. In babies who present with leukaemia cutis, evolution to systemic disease can occur over a period of months (Raney et al, 1980) . Around half of neonates with ALL also have cutaneous infiltration (Bresters et al, 2002) . As in adults, blastic plasmacytoid dendritic cell neoplasm (BPDCN) can have associated skin infiltration (Yang et al, 2012) .
The most consistent haematological feature of neonatal leukaemia is hyperleucocytosis, with counts as high as 830 9 10 9 /l (Heikinheimo et al, 1994) . Typically, affected neonates are anaemic and thrombocytopenic at birth. These haematological abnormalities usually worsen very quickly over the first few hours or days of life. As a result, neonatal leukaemia is usually readily differentiated from the reactive changes seen both in association with maternal chorioamnionitis and in babies with severe infection, particularly those who are extremely preterm (<26 weeks gestation at birth); these babies often have circulating blast cells (up to 8%) and hyperleucocytosis (>50 9 10 9 /l). Coagulation abnormalities can be present as a result either of hepatic infiltration or disseminated intravascular coagulation. The immunophenotypic features of neonatal leukaemia mirror the underlying molecular abnormalities. Because of the frequent involvement of the KMT2A gene (previously known as MLL) and the less common association with t (8;16)(p11.2;p13.3)/KAT6A-CREBBP, AML is most often acute monocytic/monoblastic or myelomonocytic. The second most common immunophenotypic subtype is acute megakaryoblastic leukaemia associated with t(1;22)(p13.3; q13.1) (see below). There are occasional cases of acute basophilic leukaemia (Kurosawa et al, 1987) , erythroleukaemia (Lasson & Goos, 1981; Allan et al, 1989; Hadjiyannakis et al, 1998; Lazure et al, 2003; Van Dongen et al, 2009; Halliday et al, 2016) , acute megakaryoblastic leukaemia without t(1;22) (Nakashima et al, 2015; Schifferli et al, 2015; Tsujimoto et al, 2015; Bertrums et al, 2017) or acute leukaemia expressing both erythroid and megakaryocytic markers (Mori et al, 1997) . Many of the reported cases with erythroid involvement were not pure erythroid leukaemia and would currently be classified as another type of AML. ALL is usually of B lineage, often with a pro-B immunophenotype, but rare cases of T lineage ALL have been reported, in one instance associated with a complex karyotype including t(1;4;22)(p11;q13;q13) (Gilgenkrantz et al, 1983) .
Differential diagnosis
The differential diagnosis of non-DS neonatal leukaemia includes leukaemoid reactions (most commonly seen in very preterm neonates, particularly when there is maternal chorioamnionitis or neonatal sepsis), stage IVS neuroblastoma) and TAM (reviewed in Roberts & Izraeli, 2014) . In practice, neonatal leukaemia is usually readily differentiated from the reactive changes seen in association with maternal chorioamnionitis and in babies with severe infection, particularly those who are extremely preterm (<26 weeks gestation at birth). In contrast to neonatal leukaemia, there is a predominance of myelocytes, metamyelocytes and neutrophils and circulating blast cells rarely exceed 8%. Furthermore, these changes usually resolve within 3-4 days of birth. Similarly, congenital infections and haemolytic disease of the newborn, which are classically included in the differential diagnosis, rarely cause diagnostic confusion because of the associated clinical features.
In clinical TAM the percentage of blasts is highly variable, from approximately 10% up to >80% (Roberts et al, 2013) . Circulating blasts in TAM are pleomorphic and sometimes, but not always, have the characteristic cytoplasmic blebbing typical of megakaryoblasts. Other clues to a diagnosis of TAM are the presence of giant platelets and megakaryocyte fragments; most neonates with TAM are not anaemic but both the platelet count and white cell count are extremely variable (Roberts & Izraeli, 2014) . These findings should prompt consideration of Down syndrome mosaicism if typical clinical features of constitutional trisomy 21 are absent. By contrast, in non-DS cases, with the exception of those associated with t(1;22), differentiation is very often monocytic/monoblastic and anaemia and thrombocytopenia are usual. Typical skin nodules, while fairly common in non-DS leukaemia, are very unusual in TAM (Gamis & Smith, 2012) and are not seen in leukaemoid reactions.
Neonatal leukaemia with KMT2A/11q23.3 rearrangement (Tables I and II) In non-DS neonatal leukaemia, the underlying cytogenetic/ molecular genetic abnormality is often t(4;11)(q21.3;q23.3)/ KMT2A-AFF1. The leukaemia may be AML (particularly acute monoblastic/monocytic or myelomonocytic leukaemia) (Bresters et al, 2002; Ishii et al, 2006) but is usually ALL (early precursor or pro-B ALL, often with coexpression of CD15 or CD33) (Bayar et al, 1996; Ishii et al, 2006; Bas Su arez et al, 2011) or MPAL (most often monocytic/monoblastic/pro-B) (Pui et al, 1987; Ridge et al, 1995) . Lineage switch can occur during treatment or at relapse, for example, cases presenting with B-lineage blasts that relapse as or 'switch' after treatment to a monoblastic immunophenotype . This suggests that the initiating mutation occurs in a stem or progenitor cell with lymphoid and myeloid lineage potential.
A significant proportion of other cases of neonatal B lineage ALL and AML involve KMT2A in a variant translocation that leads to a different fusion gene. Again, in AML the monocytic lineage is often involved. Variant 11q23.3/KMT2A translocations that have been reported in B-lineage ALL include t(9;11)(p21.3;q23.3)/KMT2A-MLLT3 and t(11;19) (q23;p13) (in early reports the 19p13 breakpoint is often not further specified but it can be p13.1 or p 13.3) (see Table I ). Lineage switch from acute monocytic leukaemia to ALL at relapse has been described in association with t(9;11)(p22; q21) (Shimizu et al, 1989) and from ALL to acute monocytic/monoblastic leukaemia in association with del(1) (p13),+add(1)(q21),add(4)(q21),-11/KMT2A rearranged (Miura et al, 2000) .
Occasionally, monozygotic twins present in the first month of life with genetically identical leukaemia, indicating an intrauterine origin with transmission from one twin to the other via intrauterine placental sharing. This has been reported in pro-B ALL with t(11;19)(q23;p13) (Mahmoud et al, 1995) , pro-B ALL with t(4;11)(q21;q23) (Bayar et al, 1996) and acute monocytic leukaemia with t(9;11)(p21;q23) (Park et al, 2001) , KMT2A rearrangement being predicted with each of these translocations. In addition, monozygotic twins presenting at 7 weeks of age had pro-B ALL associated with t(1;11)(p13;q32) and KMT2A-EPS15, suggesting that the leukaemia was already present at birth, and had spread from one twin to the other (Kotecha et al, 2012) .
Neonatal acute myeloid leukaemia not involving KMT2A/11q23.3 rearrangement (Table III) Acute megakaryoblastic leukaemia associated with t(1;22) (p13.3;q13.1)/RBM15-MKL1 characteristically occurs in childhood but neonatal cases have also been reported (see Table III ). In addition, this subtype of AML has been reported in identical twins at the age of 2 months, indicating that the leukaemia was very likely to have been present at birth (Ng et al, 1999) . The majority of reported cases have had bone marrow fibrosis (Chan et al, 1992; Lion et al, 1992; Lewis et al, 2008; Kawasaki et al, 2015) . Hepatic fibrosis has also been documented (Chan et al, 1992; Lewis et al, 2008) .
Other subtypes of AML that are more characteristic of older children and adults can, likewise, present as neonatal leukaemia, specifically t(8;21)(q22;q22.1); RUNX1-RUNX1T1 (Nanda et al, 2012) and t(8;16)(p11.2;p13.3)/KAT6A-CREBBP and variants (Table III) . Cases with t(8;16) (Schouten et al, 1983; Bernstein et al, 1987; Zandecki et al, 1988; Hanada et al, 1991; Sainati et al, 1996; Dinulos et al, 1997; Classen et al, 2005; Wong et al, 2008; Wu et al, 2011a; Coenen et al, 2013; Barrett et al, 2017) , together with those with t(1;22), are the most common subtypes of neonatal AML after cases with rearrangement of KMT2A. It is of interest that two neonates with t Review (8;16)-associated neonatal leukaemia had underlying Noonan syndrome (Wong et al, 2008; Barrett et al, 2017) .
Miscellaneous translocations or mutations that have been described in a small number of patients are shown in Table III , together with details of cases in which no cytogenetic abnormality was detected.
Neonatal blastic plasmacytoid dendritic cell neoplasm (BPDCN)
There are rare reports of neonatal BPDCN. The first reported patient had mild hepatosplenomegaly, leukaemia cutis, a white cell count of 34Á8 9 10 9 /l and trisomy 7 (Yang et al, 2012) . A second case presented with haemophagocytic lymphohistiocytosis and pancytopenia; the leukaemic phase of BPDCN with 46,XX,t(2;17;8)(p23;q23;p23) and CLTC-ALK fusion manifest at 2 months of age with the fusion gene then demonstrated to have been present at birth (Tokuda et al, 2014) .
Spontaneous remission (Table IV) Spontaneous remission of leukaemia, reminiscent of that occurring in the majority of cases of TAM, is a well-recognised feature of cases of neonatal leukaemia associated with t(8;16)/ KAT6A-CREBBP; some such cases subsequently relapse (Dinulos et al, 1997; Wong et al, 2008; Coenen et al, 2013; Barrett (Ishii et al, 2006) , t(2;4;11) (p21;q21;q23) (no molecular studies done) (Hatzipantelis et al, 2014) or t(4;11;15)(q21;q23;q22) (Tauchi et al, 2008) or t(4;11;17)(q21;q23;q11) (Bastard et al, 1985) Pro-B (early B precursor) ALL (Ishii et al, 2006) , sometimes acquiring myeloid features at relapse (Fugazza et al, 1992) t(9;11)(p21.3;q23.3)/KMT2A-MLLT3 Pro-B ALL (Ishii et al, 2006) t(11;19)(q23;p13) (McCoy et al, 1995; Bresters et al, 2002) (Imamura et al, 2002) t(10;11;19)(p11.2;q23;p13) B-lineage ALL, not further specified (Pui et al, 1987) Normal cytogenetics Pre-B ALL (Spier et al, 1984) t(X,6)(p22.1;q15) (Carney et al, 1992) , normal (Tao et al, 2000) T-ALL (Carney et al, 1992; Tao et al, 2000) Table II. Neonatal acute myeloid leukaemia with rearrangement of KMT2A Cytogenetic/molecular abnormality Characteristic features t(4;11)(q21;q23.3)/KMT2A-AFF1 Acute myelomonocytic or monoblastic leukaemia (Bresters et al, 2002 ) t(9;11)(p21.3;q23.3)/KMT2A-MLLT3
Mainly acute monoblastic leukaemia (Monpoux et al, 1996; Lee et al, 2013) ins(11;9)(q23;p22p24)/KMT2A rearranged Acute monocytic leukaemia (Zhang et al, 2006 ) t(10;11)(p13;q23.3)/KMT2A-MLLT10 Acute myelomonocytic (Pui et al, 1987) , monocytic (Kubonishi et al, 1998) or monoblastic leukaemia t(11;19)(q23.3;q13.1)/KMT2A-ELL* Acute myelomonocytic or monoblastic leukaemia (Chantrain et al, 2009) (Bayhan et al, 2015 ) t(5;11)(q21;q23)/not studied Acute monocytic leukaemia (Fernandez et al, 1999) t(10; 11)(p13; q23) Acute myelomonocytic (Pui et al, 1987) or acute monocytic/monoblastic leukaemia (Bresters et al, 2002) *In addition there are a number of other reports of neonatal leukaemia with t(11;19) without the 19p13 breakpoint or the fusion gene being fully specified. 1Á8, 11Á8, 25, 27 NA Acute megakaryoblastic leukaemia (Bain et al, 2015) 36 Hepatosplenomegaly
Acute megakaryoblastic leukaemia (Kawasaki et al, 2015) 17Á8 Hepatosplenomegaly and liver infiltration without any increase in BM blast cells t(5;6)(q31;q21) (RUNX1 duplication in second case)
Acute monoblastic leukaemia (Mayer et al, 1995) 79Á1 Leukaemia cutis, hepatosplenomegaly Acute monocytic leukaemia (Kang et al, 2014) 28Á18 Hepatosplenomegaly, respiratory distress t(6;17)(q23;q11.2) AML without maturation (Ferguson et al, 2005) 172Á7 Abdominal distention and multiorgan failure t(6;17)
Acute monocytic leukaemia (Resnik & Brod, 1993) 191 Leukaemia cutis, hepatosplenomegaly t(8;16)(p11.2;p13.3)/KAT6A-CREBBP and variants including t(1;16;8)(p13;p13;p11) (Terui et al, 2008) and cryptic insertion of CREBBP into chromosome 16 (Barrett et al, 2017) Mainly acute monoblastic or acute monocytic leukaemia (Schouten et al, 1983; Bernstein et al, 1987; Zandecki et al, 1988; Hanada et al, 1991; Sainati et al, 1996; Classen et al, 2005; Terui et al, 2008; Sung et al, 2010; Coenen et al, 2013; (cases 17, 19, 23, 43) ; Daifu et al, 2014; Hanada et al, 2016; Barrett et al, 2017) 9Á2-148, median 28Á2
Leukaemia cutis, hepatosplenomegaly; one case of leukaemia cutis and myelosarcoma without BM involvement (Classen et al, 2005) t(8;21)(p11;q22) AML with maturation (Nanda et al, 2012; Moura et al, 2015) 21 Leukaemia cutis, hepatosplenomegaly
Non-recurrent cytogenetic abnormalities t(X;6) Acute erythroleukaemia (Van Dongen et al, 2009) 155 Leukaemia cutis, hepatosplenomegaly, respiratory distress t(X;10)(q13;q11.2) Acute monocytic leukaemia (Weis et al, 1985) 200 Leukaemia cutis, hepatosplenomegaly, cardiac failure t(1;8)(p32;q21.3)/RUNX1T1 split (1 case)
Acute erythroleukaemia (Halliday et al, 2016) 72Á95 Hepatomegaly with hepatic and respiratory compromise t(2;19)(q31;q13.2)/NUP98-BCL3 NA (Moura et al, 2015) NA NA et al, 2017) but not all do so (Sainati et al, 1996; Classen et al, 2005; Terui et al, 2008; Wu et al, 2011a) . A very high white cell count does not preclude spontaneous remission. Remission is sometimes gradual, occurring over many months. By contrast, spontaneous remission is quite unusual in neonates with 11q23.3/KMT2A rearrangement. However a neonate with t(1;11)(p32;q23) and KMT2A rearrangement has been described who presented at 4 weeks of age with already regressing leukaemia cutis in the context of acute monoblastic/ monocytic leukaemia. Complete remission occurred over the next 6 weeks and was sustained at 2 years (Jesudas et al, 2017) . In another neonate with t(9;11) and leukaemia cutis, which was present at birth in the absence of peripheral blood or bone marrow disease, there was spontaneous remission, which was followed by relapse as generalised acute monoblastic leukaemia at 3 months of age (Monpoux et al, 1996) . No abnormality identified on bone marrow cytogenetic analysis Acute erythroleukaemia (Lasson & Goos, 1981) 16 Leukaemia cutis, hepatosplenomegaly Acute myelomonocytic leukaemia (Heikinheimo et al, 1994) 830 Hepatosplenomegaly, cardiac, respiratory and renal failure Acute basophilic leukaemia (Kurosawa et al, 1987) Lampkin et al (1985) 46, XY on PB Remission of cutaneous and BM disease by 6 months; relapse at 12 months with BM karyotype normal Francis et al (1989) Not successful Remission by 4 weeks, maintained at 2 years Gottesfeld et al (1989) Spontaneous remission has also been reported in a neonate with cryptic somatic 5q31.1-5q31.3 and 8q23.2q24 deletions, who had no clinical signs of leukaemia but had leucocytosis and thrombocytopenia with 20% megakaryoblasts in the peripheral blood and 30% in the bone marrow; relapse with cytogenetic evolution occurred at 11 months (Bertrums et al, 2017) . Spontaneous remission also occurred in a neonate with t(5;6)(q31;q21) (Mayer et al, 1995) and in another with a normal karyotype who had leukaemia cutis, hepatosplenomegaly, extreme hyperleucocytosis (>500 9 10 9 / l) and approximately 50% blasts in the bone marrow (Lampkin et al, 1985) . The outcome in these and other reported cases of spontaneously remitting neonatal leukaemia are summarised in Table IV In addition to spontaneous remission, babies with neonatal leukaemia have sometimes had a strikingly rapid response to initiation of chemotherapy (Odom & Gordon, 1984) , a remission following minimal chemotherapy (d 'Orazio et al, 2008; Gy arf as et al, 2016) or a sustained remission following suboptimal chemotherapy, with or without leukapheresis (Warrier et al, 1983) .
Pathogenesis and biology
The rarity of neonatal leukaemia suggests that, with the exception of those harbouring trisomy 21, fetal haemopoietic stem and progenitor cells are not inherently susceptible to leukaemic transformation. On the other hand, it seems likely that unique characteristics of fetal haemopoietic cells may make them more vulnerable to transformation by one, or a small number, of genetic events. Data mainly from studies of infant ALL but also of AML, including TAM in neonates with Down syndrome and from twin studies, provide the greatest insight into the biology of these leukaemias in early life.
It is now clear that in the majority of cases of infant ALL the mutational landscape is relatively 'silent' Andersson et al, 2015) with an average of 1Á3 mutations/case (Andersson et al, 2015) . The key molecular event that drives the leukaemia in most cases is the formation of a fusion gene involving the KMT2A (MLL) gene. Whole genome sequencing (WGS) and whole exome sequencing studies suggest that KMT2A rearrangement alone may be sufficient for the development of leukaemia in some cases (Andersson et al, 2015) . Interestingly, in this study, the two neonatal leukaemias of 22 infant ALL cases where WGS was performed had the lowest number of pathogenic variants. Similarly, in the study by Dobbins et al (2013) , of the 3 cases of infant ALL where WGS was undertaken, the single case of neonatal leukaemia had a simple translocation producing KMT2A-AFF1 (MLL-AF4) and had the lowest calculated mutation rate. While it remains possible that significant lesions were missed, e.g. in non-coding parts of the genome or for technical reasons, it is also plausible that the co-operating 'event' (2004) 46, XY on non-infiltrated BM Aleukaemic leukaemia cutis, remission by 2" months; no relapse at 1 year Eberst et al (2011) 46, XY on PB, trisomy 21 and GATA1 mutation excluded PB remission by 27 days, BM not examined, continuing remission at 24 months Nakashima et al (2015) BM, bone marrow; PB, peripheral blood. *A single dose of vincristine was given. †Normal variant.
‡A single dose of 20 mg intrathecal cytarabine was given, but no systemic chemotherapy was given as bone marrow blasts were decreasing. in some infant and congenital leukaemias is the biological characteristics of the fetal target cell. Fetal haemopoietic stem cells proliferate more than their adult counterparts and have other unique properties, such as growth factor dependence and distinct transcriptional programmes (Copley & Eaves, 2013) . These properties may provide a survival advantage to cells with few leukaemogenic molecular lesions which, if they occurred in post-natal cells, would be insufficient to cause full blown leukaemia. This seems to be the case in TAM and myeloid leukaemia of Down syndrome (ML-DS) where GATA1 mutations are acquired at high frequency in utero but not in post-natal cells (Roberts et al, 2013) , perhaps because of trisomy 21-mediated perturbation of fetal haematopoiesis (Roy et al, 2012) . On the other hand, data from a large number of studies in identical twins indicate that in utero acquisition of other leukaemogenic fusion genes, such as ETV6-RUNX1 or BCR-ABL1, leads to leukaemia later in childhood, usually after the age of 1 year (Greaves et al, 2003; Hong et al, 2011; Ma et al, 2013) . Thus, in most cases a single leukaemogenic event is not sufficient to cause leukaemia in fetal cells, suggesting that there is something particular about the leukaemogenic effects of KMT2A rearrangements in fetal cells. This is supported by the striking differences in gene expression profiles in infants aged ≤90 days at diagnosis compared to those >90 days of age (Kang et al, 2012) .
The mechanism of spontaneous remission of neonatal leukaemia has not been investigated directly. The two most likely mechanisms relate to the haemopoietic microenvironment and to the nature of the transformed cell that gives rise to the leukaemia-propagating population. Differences between the fetal and post-natal microenvironment are well recognised but relatively poorly characterised in humans. These include the likely role of the fetal liver in supporting the proliferation and/ or survival of transformed cells, particularly in Down syndrome (Roberts & Izraeli, 2014) and differences between the fetal and post-natal stromal cells, which form key components of the haemopoietic microenvironment (Martin & Bhatia, 2005; Maijenburg et al, 2012) . It is possible that an absence of the factors that maintain preleukaemic and leukaemic cells in the fetal microenvironment, may contribute to their disappearance in post-natal life. Although several fetal-specific factors have been proposed (Copley & Eaves, 2013) , their role in spontaneous remission of neonatal leukaemia remains to be determined. Similar considerations apply to the nature of the leukaemia-propagating population. It is possible that some neonatal leukaemias are initiated and propagated in progenitor cells with limited self-renewal which subsequently differentiate or die in the post-natal microenvironment. For cases that then recur, after initial resolution, it seems likely that additional, postnatally acquired mutations are then necessary to effect full leukaemic transformation, as suggested in ML-DS (Yoshida et al, 2013) and in the elegant twin studies from Mel Greaves and colleagues (Greaves et al, 2003; Ma et al, 2013) .
Management

Supportive care
Evidence to guide most aspects of supportive care in neonatal acute leukaemia is sparse. However, many reports point to the importance of careful management of hyperleucocytosis due to the high risk of associated complications, such as CNS haemorrhage and pulmonary leucocytosis. Timely exchange transfusion to reduce hyperviscosity-related symptoms may be considered but this should not delay the initiation of chemotherapy. Close monitoring of fluid balance and renal and hepatic function, in addition to the blood count and film, is essential; prematurity can exacerbate any complications (Lazure et al, 2003; Ferguson et al, 2005; Van der Linden et al, 2012; Gy arf as et al, 2016) . Tumour lysis is also a concern, especially in the context of immature renal function, and therefore careful attention to hydration is essential. Uric acid depletion with rasburicase (McNutt et al, 2006) , or allopurinol if this is unavailable, should be used (Bresters et al, 2002) but care must be taken to exclude glucose-6-phosphate dehydrogenase deficiency to avoid the risk of fatal haemolysis (Zaramella et al, 2013) . Coagulation problems are common and blood product support is often required (Bernstein et al, 1987; Bresters et al, 2002; Lewis et al, 2008; Kawasaki et al, 2015; Yarbrough et al, 2015; Gy arf as et al, 2016) .
Chemotherapy and outcome
In general, neonatal leukaemia carries an increased risk of treatment-related mortality and a high rate of relapse compared to leukaemia in older children. Nevertheless, several collaborative studies, as well as case reports, indicate that chemotherapy for neonatal leukaemia can be curative (Kawasaki et al, 2001; Van der Linden et al, 2009; Creutzig et al, 2012a) . Neonates have been eligible for both of the large collaborative treatment studies in infant ALL (Interfant-99 and the current study, Interfant-2006) (Van der Linden et al, 2009; Pui et al, 2015) and also for international collaborative studies in AML (AML-BFM-98, AML-BFM-2004 and the current study AML-BFM-2012) (Creutzig et al, 2012b . In the larger studies, the outcome for all children under the age of 6, 12 months or 2 years has been considered together, with the exception of Interfant-1999 where data specific for neonatal leukaemia has been reported ( Van der Linden et al, 2009) . The need for international collaborative studies to improve existing treatment regimens and investigate new therapeutic approaches in rare sub-groups of childhood leukaemia has recently been emphasised both in ALL and AML (Creutzig et al, 2012b; Pui et al, 2015; Zwaan et al, 2015) .
Two additional general points deserve emphasis. First, several studies have specified reduced doses of all or most of the chemotherapeutic agents in children <3 months of age (e.g. Interfant-99 and Interfant-2006) . This is logical given consistent reports of increased treatment-related toxicity, particularly in neonates (Creutzig et al, 2012b; Van der Linden et al, 2012) . In the Interfant studies, doses are reduced to two-thirds of the doses given to older infants and are calculated based on surface area rather than mg/kg. Similar dose reductions for neonates have not generally been written in to treatment protocols for AML. However, it is important to note there are very few pharmacokinetic studies of anti-cancer drugs in neonates and very little is known about drug disposition in young infants (Veal & Boddy, 2012) . Systematic clinical pharmacology studies are therefore needed to help inform the design of future leukaemia trials involving this age group.
Second, the overall approach to chemotherapy differs in AML, where the possibility of spontaneous remission must be considered, particularly in children with t(8;16) (Coenen et al, 2013) . In the Dutch series, leukaemia regressed without chemotherapy in approximately 5% of neonates (Bresters et al, 2002 ) (see Table IV ). In a more recent case series of children with t(8;16), all 7 neonatal cases receiving no treatment regressed spontaneously (Coenen et al, 2013) . Nevertheless, caution is required, as 4 of these children subsequently required chemotherapy due to relapse. Thus, careful monitoring of any child with spontaneous remission of neonatal leukaemia is essential. Importantly, other neonates with the same translocation have presented with an aggressive course (Sung et al, 2010; Daifu et al, 2014) , and thus there is currently no clear guidance as to which children can avoid the burden of chemotherapy. However, in neonates who are well and stable, it seems reasonable to defer intensive chemotherapy until the disease course evolves provided the child remains well.
For neonatal ALL, most cases published since 2000 have been treated with combination chemotherapy, usually following a protocol similar to or identical to that used for infant ALL (Bresters et al, 2002; Ishii et al, 2006; Van der Linden et al, 2009; Bas Su arez et al, 2011; Hatzipantelis et al, 2014) . In the largest published series, 30 children treated with the Interfant-99 protocol received a 'hybrid' regimen combining ALL treatment (corticosteroids, vincristine, asparaginase, mercaptopurine and methotrexate) with elements designed for AML treatment (anthracyclines and cytarabine). This gave a 2-year event-free survival of 20% but the survival at last follow-up was not significantly worse than that of older infants in the same trial. Importantly, the toxicity was also similar in the neonatal cases compared to the older infants but, perhaps because of the biological characteristics of the neonatal cases (including the CD10-negative immunophenotype and high white cell count) the relapse rate was extremely high: 19/26 cases (73%) where complete remission was achieved relapsed and this was significantly higher than in the older infants (Van der Linden et al, 2009) . Although some children with relapsed infant ALL may achieve a second remission (Tomizawa et al, 2009; Driessen et al, 2016) , the small numbers of surviving children make it difficult to assess the best approach to salvage therapy for neonatal ALL. Interestingly, in a study from the Japanese Infant Leukaemia Study Group, 3 of the 8 cases of neonatal ALL were reported to be alive in complete remission more than 3 years after diagnosis following haemopoietic stem cell transplantation (HSCT) in first (n = 2) or second (n = 1) remission, indicating that HSCT is feasible in this situation and can be curative (Ishii et al, 2006) .
For neonatal AML, cases published since 2000 have generally been treated with combination chemotherapy (cytarabine, etoposide and an anthracycline) plus CNS-directed therapy (Kawasaki et al, 2001; Bresters et al, 2002; Duchayne et al, 2003; Ishii et al, 2006; Lewis et al, 2008; Sung et al, 2010; Agrawal et al, 2011; Nanda et al, 2012; Kang et al, 2014; Bain et al, 2015; Hanada et al, 2016) . The largest study reported 125 infants with AML treated on AML-BFM-98 and AML-BFM-2004 and included 26 infants aged <3 months (Creutzig et al, 2012a) . The 5-year overall survival and event-free survival was 51 AE 6% and 44 AE 6%, respectively, and there was no difference in overall or event-free survival and relapse in the infants aged 0-3 months compared to those aged 4-6, 7-9 or 10-12 months (Creutzig et al, 2012a) . These results are encouraging given older data that report overall survival in neonatal AML to be similar to that in neonatal ALL at 20-25% (Bresters et al, 2002) . HSCT has been successfully used in some high-risk cases. Of the 3 children with neonatal AML reported by the Japanese Infant Leukaemia Study Group, the only long-term survivor was the child who underwent HSCT in first remission (Ishii et al, 2006) . However, the role of HSCT in first or second remission of neonatal AML is not clear because there are too few reported cases.
There is limited information specifically about the late effects of chemotherapy for neonatal leukaemia given both the rarity of the condition and the low rate of long-term survival. Leung et al (2000) reported a high frequency of late effects in a study of 34 long-term survivors of infant leukaemia, including 19 treated for infant ALL and 15 treated for infant AML. Only 8 (24%) of these children had no evidence of late effects and the most common late effects were related to growth (66%), learning (50%), hypothyroidism (15%) and pubertal development (12%); however, neonatal leukaemia cases were not separately identified. In the review of infant AML cases from AML-BFM-98 and AML-BFM-2004, Creutzig et al (2012b) also reported a high cumulative incidence of late effects in infants surviving for at least 1Á5 years (67/81; 83%), including 2 patients who developed second malignancies. This study also did not separately identify those cases presenting in the neonatal period rather than later in infancy. 
Conclusions
Neonatal leukaemia has many distinctive features. It has an intrauterine origin and there is often advanced disease at presentation. Hepatomegaly, splenomegaly, cutaneous infiltration, CNS infiltration and hyperleucocytosis are common features. The leukaemia is more often myeloid than lymphoid. There is a strong association with translocations leading to rearrangement of KMT2A and therefore with acute leukaemia with monocytic differentiation; less often there is t(8;16)(p11.2;p13.3) with acute monocytic leukaemia, often with erythrophagocytosis, or t(1;22)(p13.3;q13.1) with acute megakaryoblastic leukaemia. A minority of cases, particularly those associated with KMT2A rearrangement, are of mixed phenotype, or show lineage switch at relapse and may cause diagnostic confusion. Spontaneous remission is more likely to occur than in older infants and children, and is particularly associated with t(8;16); sometimes the remission is sustained but careful monitoring is advised as relapse can occur. Neonatal ALL and AML can both be cured by chemotherapy although the risk of relapse and treatment-related toxicity are both much higher than in older children. The rarity of neonatal leukaemia means that international collaborative studies are needed to improve existing treatment regimens and investigate new therapeutic approaches.
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